Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Figure 3

Impact of ATM expression levels on long-term survival. (A) Kaplan-Meier curves showing long-term survival among breast cancer patients treated with doxorubicin or a combination of 5-fluorouracil and mitomycin in the neoadjuvant setting (Cohort 1), stratified by ATM expression levels (above/below median) and TP53 mutation status. (B) Data corresponding to (A), but in a cohort of epirubicin treated patients (Cohort 2). (C, D) Data corresponding to (A) and (B), but where mutated status is defined as TP53 mutation affecting the L2/L3 domains or CHEK2 mutation.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us